fluticasone furoate/umeclidinium/vilanterol vs Umeclidinium

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline

fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta

Marketed by GlaxoSmithKline

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Reliable signal

NCT02164513 · Phase 3 · completed

This was a large randomized, double-blind, active-controlled trial in 10,355 COPD patients at 971 sites in 37 countries; the primary endpoint, annual on-treatment moderate/severe exacerbation rate, is a hard clinical outcome, and triple therapy significantly reduced exacerbations versus both dual-therapy comparators (rate ratio 0.75 vs UMEC/VI and 0.85 vs FF/VI, both p<0.001).

Next expected readout: September 2027 · NCT07192016 (registry estimate)

Reported efficacy

Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI (Up to Week 52): Annual rate of on-treatment moderate/severe exacerbations: FF/UMEC/VI 0.91/yr vs FF/VI 1.07/yr (rate ratio 0.85, 95% CI 0.80-0.90, 15% reduction, p<0.001) vs UMEC/VI 1.21/yr (rate ratio 0.75, 95% CI 0.70-0.81, 25% reduction, p<0.001) (met)

Result source: NCT02164513

Umeclidinium · Incruse Ellipta

Marketed by GlaxoSmithKline

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule
Reliable signal

NCT02184611 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial in 308 patients using lung function (trough FEV1) as its primary measure, and umeclidinium produced a significantly greater improvement than placebo (least-squares mean difference 0.154 L, 95% CI 0.113 to 0.194, p<0.001).

Reported efficacy

Change From Baseline in Trough (Pre-bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) on Treatment Day 169 (Baseline (Day 1) and Day 169): Change from baseline in trough FEV1 at Day 169 (primary endpoint): UMEC 62.5 mcg vs placebo, LS mean treatment difference 154 mL (95% CI 113, 194; p<0.001) (met)

Result source: NCT02184611

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfluticasone furoate/​umeclidinium/​vilanterolUmeclidinium
Moderate or severe exacerbations, annualised rate0.9 vs 1.1vs FF/VIwk 52 · n 4145NCT02164513
2 other results
  • 0.2 vs 0.3 100/62.5/25 µg · wk 24 · n 907 · Phase 3 · secondary NCT02345161
  • 0.2 vs 0.4 100/62.5/25 µg · wk 52 · n 210 · Phase 3 · secondary NCT02345161
—Trial running · NCT06474039
Trough FEV1, change0.1 vs -0.0vs BUD/FOR100/62.5/25 µg · wk 24 · n 836NCT02345161
14 other results
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.1 vs -0.1 100/62.5/25 µg · wk 52 · n 183 · Phase 3 · primary NCT02345161
  • 0.1 vs -0.0 wk 52 · n 3366 · Phase 3 · secondary NCT02164513
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 362 · Phase 4 · primary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 376 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs -0.0 100/62.5/25 mcg · wk 4 · n 385 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 358 · Phase 4 · secondary NCT03478683
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 0.29 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs 0.0 100/62.5/25 mcg · wk 0.29 · n 358 · Phase 4 · secondary NCT03478683
0.1 vs -0.0+0.2 vs placebo62.5 mcg · wk 24 · n 176NCT02184611
21 other results
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12.14 · n 183 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 188 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12 · n 184 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 62.5 µg QD · wk 12.14 · n 178 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 62.5 µg QD · wk 12 · n 190 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 199 · Phase 3 · primary NCT02119286
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT02119286
  • 0.2 vs 0.1 62.5 mcg QD · wk 12.14 · n 392 · Phase 3 · primary NCT02207829
  • 0.2 vs 0.2 62.5/25 µg · wk 12.14 · n 392 · Phase 3 · primary NCT02257385
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.2 vs 0.0 62.5/25 mcg · wk 12 · n 227 · Phase 3 · secondary NCT02152605
  • 0.2 vs 0.1 62.5/25 mcg · wk 12.14 · n 349 · Phase 3 · secondary NCT01879410
  • 0.1 vs -0.0 62.5 mcg+ICS/LABA · wk 12 · n 109 · Phase 4 · primary NCT02257372
  • 0.1 vs -0.0 62.5/25 mcg · wk 24 · n 691 · Phase 4 · primary NCT03034915
  • 0.1 vs 0.1 62.5 mcg QD · wk 12 · n 431 · Phase 4 · primary NCT02236611
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539
  • 0.2 vs -0.0 62.5/25 mcg · wk 12 · n 175 · Phase 4 · secondary NCT02275052
SGRQ total, change-6.6 vs -4.3vs BUD/FOR100/62.5/25 µg · wk 24 · n 846NCT02345161
3 other results
  • -4.6 vs -1.9 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · primary NCT02345161
  • -5.5 vs -3.7 wk 52 · n 3318 · Phase 3 · secondary NCT02164513
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
-6.2 vs -2.1−4 vs placebo62.5/25 mcg · wk 12 · n 212NCT02152605
5 other results
  • -7.3 vs -4.3 62.5 mcg · wk 24 · n 205 · Phase 3 · secondary NCT02184611
  • -7.0 vs -2.5 62.5 mcg · wk 12 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -1.4 62.5 mcg · wk 4 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
  • -5.0 vs -3.3 62.5/25 mcg · wk 24 · n 704 · Phase 4 · secondary NCT03034915
TDI focal score2.3 vs 1.7vs BUD/FOR100/62.5/25 µg · wk 24 · n 839NCT02345161
1 other result
  • 1.7 vs 1.4 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · secondary NCT02345161
2.5 vs 1.6+0.9 vs placebo62.5 mcg · wk 24 · n 176NCT02184611

Moderate or severe exacerbations, annualised rate

fluticasone furoate/​umeclidinium/​vilanterol
0.9 vs 1.1vs FF/VIwk 52 · n 4145NCT02164513
2 other results
  • 0.2 vs 0.3 100/62.5/25 µg · wk 24 · n 907 · Phase 3 · secondary NCT02345161
  • 0.2 vs 0.4 100/62.5/25 µg · wk 52 · n 210 · Phase 3 · secondary NCT02345161
Umeclidinium
—Trial running · NCT06474039

Trough FEV1, change

fluticasone furoate/​umeclidinium/​vilanterol
0.1 vs -0.0vs BUD/FOR100/62.5/25 µg · wk 24 · n 836NCT02345161
14 other results
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.1 vs -0.1 100/62.5/25 µg · wk 52 · n 183 · Phase 3 · primary NCT02345161
  • 0.1 vs -0.0 wk 52 · n 3366 · Phase 3 · secondary NCT02164513
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 362 · Phase 4 · primary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 376 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs -0.0 100/62.5/25 mcg · wk 4 · n 385 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 358 · Phase 4 · secondary NCT03478683
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 0.29 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs 0.0 100/62.5/25 mcg · wk 0.29 · n 358 · Phase 4 · secondary NCT03478683
Umeclidinium
0.1 vs -0.0+0.2 vs placebo62.5 mcg · wk 24 · n 176NCT02184611
21 other results
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12.14 · n 183 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 188 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12 · n 184 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 62.5 µg QD · wk 12.14 · n 178 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 62.5 µg QD · wk 12 · n 190 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 199 · Phase 3 · primary NCT02119286
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT02119286
  • 0.2 vs 0.1 62.5 mcg QD · wk 12.14 · n 392 · Phase 3 · primary NCT02207829
  • 0.2 vs 0.2 62.5/25 µg · wk 12.14 · n 392 · Phase 3 · primary NCT02257385
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.2 vs 0.0 62.5/25 mcg · wk 12 · n 227 · Phase 3 · secondary NCT02152605
  • 0.2 vs 0.1 62.5/25 mcg · wk 12.14 · n 349 · Phase 3 · secondary NCT01879410
  • 0.1 vs -0.0 62.5 mcg+ICS/LABA · wk 12 · n 109 · Phase 4 · primary NCT02257372
  • 0.1 vs -0.0 62.5/25 mcg · wk 24 · n 691 · Phase 4 · primary NCT03034915
  • 0.1 vs 0.1 62.5 mcg QD · wk 12 · n 431 · Phase 4 · primary NCT02236611
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539
  • 0.2 vs -0.0 62.5/25 mcg · wk 12 · n 175 · Phase 4 · secondary NCT02275052

SGRQ total, change

fluticasone furoate/​umeclidinium/​vilanterol
-6.6 vs -4.3vs BUD/FOR100/62.5/25 µg · wk 24 · n 846NCT02345161
3 other results
  • -4.6 vs -1.9 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · primary NCT02345161
  • -5.5 vs -3.7 wk 52 · n 3318 · Phase 3 · secondary NCT02164513
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
Umeclidinium
-6.2 vs -2.1−4 vs placebo62.5/25 mcg · wk 12 · n 212NCT02152605
5 other results
  • -7.3 vs -4.3 62.5 mcg · wk 24 · n 205 · Phase 3 · secondary NCT02184611
  • -7.0 vs -2.5 62.5 mcg · wk 12 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -1.4 62.5 mcg · wk 4 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
  • -5.0 vs -3.3 62.5/25 mcg · wk 24 · n 704 · Phase 4 · secondary NCT03034915

TDI focal score

fluticasone furoate/​umeclidinium/​vilanterol
2.3 vs 1.7vs BUD/FOR100/62.5/25 µg · wk 24 · n 839NCT02345161
1 other result
  • 1.7 vs 1.4 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · secondary NCT02345161
Umeclidinium
2.5 vs 1.6+0.9 vs placebo62.5 mcg · wk 24 · n 176NCT02184611
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety

Coverage. fluticasone furoate/umeclidinium/vilanterol: 10 of 10 rows · Umeclidinium: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfluticasone furoate/​umeclidinium/​vilanterol
Rows use multiple source trials
Umeclidinium
Rows use multiple source trials
CAT
responder rate · % of participants
47.5% (n=1539) vs 39.9% (n=1543) Non-Ellipta @ 24wk*100 mcg/62.5 mcg/25 mcg by ELLIPTA DPIa,b,c
Responders
NCT03467425 · Phase 4 · registry result, not featured evidence · converted to % from 731 Participants as posted
55% (n=812) vs 48% (n=804) UMEC @ 24wk62.5/25 mcga,b,c
NCT03034915 · Phase 4 · registry result, not featured evidence
FEV1 Wm0 24 h
absolute change · L
0.039 vs 0.029 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcgd,e,b,c
NCT03478696 · Phase 4 · registry result, not featured evidence
show 1 more dose
0.04 vs 0.023 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
0.213 vs 0.112 FSC L @ 12wk62.5/25 mcge,b,c
NCT01879410 · Phase 3 · registry result, not featured evidence
SGRQ
responder rate · % of participants
50% (n=489) vs 51% (n=483) FF/VI + UMEC @ 24wk100/62.5/25f,b,c
NCT02729051 · Phase 3 · registry result, not featured evidence
45% (n=811) vs 41% (n=802) UMEC @ 24wk62.5/25 mcgf,b,c
NCT03034915 · Phase 4 · registry result, not featured evidence
1 other source trial
50% (n=489) vs 51% (n=483) FF/VI + UMEC @ 24wk100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
TDI Focal
responder rate · % of participants
56% (n=482) vs 56% (n=481) FF/VI + UMEC @ 24wk100/62.5/25f,b,c
NCT02729051 · Phase 3 · registry result, not featured evidence
50% (n=806) vs 42% (n=799) UMEC @ 24wk62.5/25 mcgf,b,c
NCT03034915 · Phase 4 · registry result, not featured evidence
1 other source trial
56% (n=482) vs 56% (n=481) FF/VI + UMEC @ 24wk100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
TDI Total
absolute value · score
2.029 vs 1.892 FF/VI + UMEC score @ 24wk100/62.5/25b,c
NCT02729051 · Phase 3 · registry result, not featured evidence
2.029 vs 1.892 FF/VI + UMEC score @ 24wk100/62.5/25b,c
NCT02729051 · Phase 3 · registry result, not featured evidence
Time to First Moderate or Severe Exacerbation
time to event · months
NA vs NA FF/VI + UMEC months100/62.5/25b,c,g
NCT02729051 · Phase 3 · registry result, not featured evidence
NA vs NA FF/VI + UMEC months100/62.5/25b,c,g
NCT02729051 · Phase 3 · registry result, not featured evidence
Dropout rate
10.5%FF/UMEC/VIh
NCT02164513 · Phase 3
show 9 more results
—100/62.5/25
NCT02164513 · Phase 3
4.9%100/62.5/25 µg
NCT02345161 · Phase 3
6.1%
NCT04923347 · Phase 4 · registry result, not featured evidence
9.5%
NCT05535972 · Phase 4 · registry result, not featured evidence
3%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
NCT03467425 · Phase 4 · registry result, not featured evidence
4.3%100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
4.6%100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
3.6%100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
5.7%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
13.7%62.5 mcgi
NCT02184611 · Phase 3
show 25 more results
8.9%125 µg QD
NCT01772147 · Phase 3 · combination
12.3%62.5 µg QD
NCT01772147 · Phase 3 · combination
5.3%62.5 µg
NCT01957163 · Phase 3 · combination
8.7%125 µg
NCT01957163 · Phase 3 · combination
3.4%125 µg
NCT02119286 · Phase 3 · combination
5.3%62.5 µg
NCT02119286 · Phase 3 · combination
10.7%125 µg QD
NCT01772134 · Phase 3 · combination
6.9%62.5 µg QD
NCT01772134 · Phase 3 · combination
11.7%62.5/25 mcg
NCT03034915 · Phase 4 · registry result, not featured evidence
—62.5/25 mcg
NCT02275052 · Phase 4 · registry result, not featured evidence
5%62.5 mcg QD
NCT02236611 · Phase 4 · registry result, not featured evidence
8.4%62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
5.7%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
8.3%62.5 mcg QD
NCT02207829 · Phase 3 · registry result, not featured evidence
4.6%62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
7.3%62.5/25 mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25 mcg
NCT01879410 · Phase 3 · registry result, not featured evidence
—62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
—62.5/25 µg once daily
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
3.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
4.3%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
2.5%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
3.9%FF/UMEC/VIh
NCT02164513 · Phase 3
show 9 more results
—100/62.5/25
NCT02164513 · Phase 3
1.8%100/62.5/25 µg
NCT02345161 · Phase 3
—
NCT04923347 · Phase 4 · registry result, not featured evidence
1.3%
NCT05535972 · Phase 4 · registry result, not featured evidence
0.6%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
NCT03467425 · Phase 4 · registry result, not featured evidence
1.5%100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
0.3%100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
1.4%100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
2.4%62.5 mcgi
NCT02184611 · Phase 3
show 25 more results
3%125 µg QD
NCT01772147 · Phase 3 · combination
4.9%62.5 µg QD
NCT01772147 · Phase 3 · combination
1%62.5 µg
NCT01957163 · Phase 3 · combination
1.9%125 µg
NCT01957163 · Phase 3 · combination
1%125 µg
NCT02119286 · Phase 3 · combination
3.4%62.5 µg
NCT02119286 · Phase 3 · combination
4.9%125 µg QD
NCT01772134 · Phase 3 · combination
2.5%62.5 µg QD
NCT01772134 · Phase 3 · combination
3.6%62.5/25 mcg
NCT03034915 · Phase 4 · registry result, not featured evidence
—62.5/25 mcg
NCT02275052 · Phase 4 · registry result, not featured evidence
1.9%62.5 mcg QD
NCT02236611 · Phase 4 · registry result, not featured evidence
5.9%62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
2%62.5 mcg QD
NCT02207829 · Phase 3 · registry result, not featured evidence
2.5%62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
3.2%62.5/25 mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25 mcg
NCT01879410 · Phase 3 · registry result, not featured evidence
—62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
—62.5/25 µg once daily
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
—100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
—FF/UMEC/VIh
NCT02164513 · Phase 3
show 9 more results
21.6%100/62.5/25
NCT02164513 · Phase 3
6.7%100/62.5/25 µg
NCT02345161 · Phase 3
0.4%
NCT04923347 · Phase 4 · registry result, not featured evidence
4.1%
NCT05535972 · Phase 4 · registry result, not featured evidence
7.4%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
NCT03467425 · Phase 4 · registry result, not featured evidence
3.3%100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
4.4%100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
8%100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
10.4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
8.3%62.5 mcgi
NCT02184611 · Phase 3
show 25 more results
3%125 µg QD
NCT01772147 · Phase 3 · combination
3%62.5 µg QD
NCT01772147 · Phase 3 · combination
1%62.5 µg
NCT01957163 · Phase 3 · combination
3.4%125 µg
NCT01957163 · Phase 3 · combination
1.4%125 µg
NCT02119286 · Phase 3 · combination
3.9%62.5 µg
NCT02119286 · Phase 3 · combination
2.9%125 µg QD
NCT01772134 · Phase 3 · combination
2%62.5 µg QD
NCT01772134 · Phase 3 · combination
6%62.5/25 mcg
NCT03034915 · Phase 4 · registry result, not featured evidence
3%62.5/25 mcg
NCT02275052 · Phase 4 · registry result, not featured evidence
3.3%62.5 mcg QD
NCT02236611 · Phase 4 · registry result, not featured evidence
5%62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
10.4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
3.3%62.5 mcg QD
NCT02207829 · Phase 3 · registry result, not featured evidence
4.4%62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
—62.5/25 mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
6.9%62.5/25mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
3.2%62.5/25 mcg
NCT01879410 · Phase 3 · registry result, not featured evidence
0.5%62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
1.7%62.5/25 µg once daily
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
0.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
100/62.5/25h
viral upper respiratory tract infection 12.5%
upper respiratory tract infection 7.2%
headache 5.6%
NCT02164513 · Phase 3
show 8 more results
100/62.5/25 µg
nasopharyngitis 7.9%
headache 4.8%
NCT02345161 · Phase 3
pyrexia 4.4%
headache 3.9%
NCT04923347 · Phase 4 · registry result, not featured evidence
dysphonia 0.4%
abdominal discomfort 0.2%
abdominal pain upper 0.2%
NCT05535972 · Phase 4 · registry result, not featured evidence
100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
dyspnoea 2.1%
NCT03467425 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
headache 4.5%
nasopharyngitis 4%
NCT03474081 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
headache 3.6%
nasopharyngitis 1.9%
NCT03478696 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
nasopharyngitis 5%
NCT03478683 · Phase 4 · registry result, not featured evidence
100/62.5/25
viral upper respiratory tract infection 10.6%
headache 6.1%
upper respiratory tract infection 3.4%
NCT02729051 · Phase 3 · registry result, not featured evidence
62.5 mcgi
upper respiratory tract infection 12.2% (placebo 12.9%)
nasopharyngitis 9.3% (placebo 10.9%)
dizziness 2.9% (placebo 2%)
NCT02184611 · Phase 3
show 23 more results
125 µg QD
nasopharyngitis 5% (placebo 4.5%)
headache 3% (placebo 4.5%)
NCT01772147 · Phase 3 · combination
62.5 µg QD
headache 4.4% (placebo 4.5%)
nasopharyngitis 3% (placebo 4.5%)
NCT01772147 · Phase 3 · combination
62.5 µg
headache 4.4% (placebo 2.9%)
back pain 3.4% (placebo 1.5%)
nasopharyngitis 3.4% (placebo 3.4%)
NCT01957163 · Phase 3 · combination
125 µg
nasopharyngitis 4.8% (placebo 3.4%)
headache 4.3% (placebo 2.9%)
cough 3.4% (placebo 0.5%)
NCT01957163 · Phase 3 · combination
125 µg
nasopharyngitis 9.2% (placebo 10.7%)
headache 1.9% (placebo 2.4%)
back pain 1% (placebo 1.9%)
NCT02119286 · Phase 3 · combination
62.5 µg
nasopharyngitis 5.3% (placebo 10.7%)
back pain 3.9% (placebo 1.9%)
headache 3.9% (placebo 2.4%)
NCT02119286 · Phase 3 · combination
125 µg QD
headache 6.3% (placebo 4.9%)
cough 2.4% (placebo 1.5%)
nasopharyngitis 2.4% (placebo 4.9%)
NCT01772134 · Phase 3 · combination
62.5 µg QD
headache 4.4% (placebo 4.9%)
cough 3.4% (placebo 1.5%)
nasopharyngitis 2.5% (placebo 4.9%)
NCT01772134 · Phase 3 · combination
62.5/25 mcg
nasopharyngitis 8.4%
NCT03034915 · Phase 4 · registry result, not featured evidence
62.5 mcg QD
headache 8.1%
nasopharyngitis 8.1%
NCT02236611 · Phase 4 · registry result, not featured evidence
62.5 mcg+ICS/LABA
nasopharyngitis 13.4% (placebo 14.5%)
headache 3.4% (placebo 6.8%)
cough 2.5% (placebo 4.3%)
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
100/62.5/25
viral upper respiratory tract infection 10.6%
headache 6.1%
upper respiratory tract infection 3.4%
NCT02729051 · Phase 3 · registry result, not featured evidence
62.5 mcg QD
headache 5.9%
nasopharyngitis 5.3%
NCT02207829 · Phase 3 · registry result, not featured evidence
62.5/25 µg
headache 7.5%
nasopharyngitis 6.6%
cough 3.3%
NCT02257385 · Phase 3 · registry result, not featured evidence
62.5/25mcg
headache 6.5% (placebo 6.5%)
nasopharyngitis 5.2% (placebo 6.5%)
NCT02152605 · Phase 3 · registry result, not featured evidence
62.5/25 mcg
headache 6.9%
nasopharyngitis 4%
NCT01879410 · Phase 3 · registry result, not featured evidence
62.5/25 µg
headache 5%
NCT02014480 · Phase 3 · registry result, not featured evidence
62.5/25 µg once daily
nasopharyngitis 4%
headache 3.5%
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
100/250 µg
nasopharyngitis 1.9%
toothache 0.5%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/125 µg
dysphonia 6.5%
nasopharyngitis 4.3%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/15.6 µg
nasopharyngitis 7.1%
toothache 7.1%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/62.5 µg
nasopharyngitis 5%
dysphonia 2.5%
toothache 2.5%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/250/25 µg
dysphonia 0%
nasopharyngitis 0%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aThe reported result categories differ.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eTrial phases differ: Phase 4 versus Phase 3.
  6. fTrial phases differ: Phase 3 versus Phase 4.
  7. gThe assessment timepoint is not available for both results.
  8. hPopulation comparability has not been reviewed for these studies.
  9. iPopulation comparability has not been reviewed for 25 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

fluticasone furoate/umeclidinium/vilanterol

Moderate or Severe Exacerbation Rate Annualized 0.91 vs 1.07 FF/VI per year @ 52wk
event rate · per year
NCT02164513 · Phase 3
show 2 more results
0.22 vs 0.34 BUD/FOR per year @ 24wk100/62.5/25 µg
NCT02345161 · Phase 3
0.2 vs 0.36 BUD/FOR per year @ 52wk100/62.5/25 µg
NCT02345161 · Phase 3
Time to First Moderate or Severe Exacerbation NA vs NA FF/VI months @ 52wk
time to event · months
Median time to onset
NCT02164513 · Phase 3
show 1 more result
NA vs 8.31 UMEC/VI months @ 52wk
Median time to onset
NCT02164513 · Phase 3
EXACT-RS -1.45 vs -0.5 BUD/FOR score @ 4wk100/62.5/25 µg
absolute change · score
NCT02345161 · Phase 3
show 17 more results
-2 vs -0.77 BUD/FOR score @ 8wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.23 vs -1.05 BUD/FOR score @ 12wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.42 vs -1.09 BUD/FOR score @ 16wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.43 vs -1.02 BUD/FOR score @ 20wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.31 vs -0.96 BUD/FOR score @ 24wk100/62.5/25 µg
NCT02345161 · Phase 3
-1.24 vs -0.72 BUD/FOR score @ 4wk100/62.5/25 µg
NCT02345161 · Phase 3
-1.97 vs -0.9 BUD/FOR score @ 8wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.18 vs -1.21 BUD/FOR score @ 12wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.53 vs -1.52 BUD/FOR score @ 16wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.64 vs -1.53 BUD/FOR score @ 20wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.63 vs -1.52 BUD/FOR score @ 24wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.48 vs -1.16 BUD/FOR score @ 28wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.33 vs -0.9 BUD/FOR score @ 32wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.12 vs -0.62 BUD/FOR score @ 36wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.34 vs -1.11 BUD/FOR score @ 40wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.3 vs -0.81 BUD/FOR score @ 44wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.17 vs -0.64 BUD/FOR score @ 48wk100/62.5/25 µg
NCT02345161 · Phase 3
EXACT-RS -2.03 vs -0.61 BUD/FOR score @ 52wk100/62.5/25 µg
absolute change · score
EXACT-RS Scores, Week 49-52, n=179, 171
NCT02345161 · Phase 3
FEV1 Trough 0.0542 L @ 4wk
absolute change · L
No placebo or comparator arm
CFB to Day 28
NCT04923347 · Phase 4 · registry result, not featured evidence
FEV1 Trough 0.0317 L @ 12wk
absolute change · L
No placebo or comparator arm
CFB to Day 85
NCT04923347 · Phase 4 · registry result, not featured evidence
CAT Total -6.8 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence
show 1 more result
-4.4 score @ 4wk
NCT05535972 · Phase 4 · registry result, not featured evidence
mMRC Dyspnea Scale -0.5 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence
show 1 more result
-0.5 score @ 12wk
NCT05535972 · Phase 4 · registry result, not featured evidence
FEV1 0.132 L @ 12wk
absolute change · L
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence
CAT 86% (n=422) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence
FEV1 1.446 vs 1.396 Non-Ellipta L @ 24wk100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
absolute change · L
NCT03467425 · Phase 4 · registry result, not featured evidence

Umeclidinium

FEV1 Wm0 6 h 0.136 vs 0.011 placebo L @ 0wk62.5 mcg
absolute change · L
NCT02184611 · Phase 3
show 10 more results
0.187 vs 0.034 placebo L @ 12wk62.5 µg
NCT01957163 · Phase 3 · combination
0.184 vs 0.035 placebo L @ 12wk62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
0.235 vs 0.258 Indacaterol + Tiotropium Bromide L @ 12wk62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
0.217 vs 0.052 placebo L @ 12wk125 µg QD
NCT01772147 · Phase 3 · combination
0.175 vs 0.034 placebo L @ 12wk125 µg
NCT01957163 · Phase 3 · combination
0.192 vs 0.032 placebo L @ 12wk125 µg QD
NCT01772134 · Phase 3 · combination
0.196 vs 0.052 placebo L @ 12wk62.5 µg QD
NCT01772147 · Phase 3 · combination
0.196 vs 0.032 placebo L @ 12wk62.5 µg QD
NCT01772134 · Phase 3 · combination
0.152 vs 0.017 placebo L @ 12wk125 µg
NCT02119286 · Phase 3 · combination
0.164 vs 0.017 placebo L @ 12wk62.5 µg
NCT02119286 · Phase 3 · combination
CAT Total -1.75 vs -0.26 placebo score @ 4wk62.5 mcg
absolute change · score
NCT02184611 · Phase 3
show 2 more results
-2.18 vs -0.08 placebo score @ 12wk62.5 mcg
NCT02184611 · Phase 3
-2 vs -1.32 placebo score @ 24wk62.5 mcg
NCT02184611 · Phase 3
Rescue-free 24-h Period 15.2 vs 1.9 placebo % of time @ 12wk125 µg QD
percent change · % of time
NCT01772147 · Phase 3 · combination
show 1 more result
8.4 vs 1.9 placebo % of time @ 12wk62.5 µg QD
NCT01772147 · Phase 3 · combination
Rescue Puffs -0.7 vs -0.2 placebo puffs @ 12wk125 µg QD
absolute change · puffs
NCT01772147 · Phase 3 · combination
show 3 more results
-0.5 vs -0.2 placebo puffs @ 12wk125 µg QD
NCT01772134 · Phase 3 · combination
-0.4 vs -0.2 placebo puffs @ 12wk62.5 µg QD
NCT01772147 · Phase 3 · combination
-0.5 vs -0.2 placebo puffs @ 12wk62.5 µg QD
NCT01772134 · Phase 3 · combination
Rescue-free 24 h Periods 11.1 vs 4.9 placebo % of time @ 12wk125 µg QD
absolute change · % of time
NCT01772134 · Phase 3 · combination
show 1 more result
13.3 vs 4.9 placebo % of time @ 12wk62.5 µg QD
NCT01772134 · Phase 3 · combination
TDI Focal 1.68 vs 1.3 UMEC score @ 24wk62.5/25 mcg
absolute value · score
NCT03034915 · Phase 4 · registry result, not featured evidence
E-RS Total -1.52 vs -0.99 UMEC score @ 24wk62.5/25 mcg
absolute change · score
NCT03034915 · Phase 4 · registry result, not featured evidence
show 4 more results
-1.5 vs 0.5 FF score @ 4wk100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-1.5 vs 0.5 FF score @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-2.6 vs 0.5 FF score @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-2.5 vs 0.5 FF score @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
E-RS Cough Sputum Domain -0.45 vs -0.38 UMEC score @ 24wk62.5/25 mcg
absolute change · score
RS-CSP
NCT03034915 · Phase 4 · registry result, not featured evidence
E-RS 36% (n=809) vs 27% (n=800) UMEC @ 24wk62.5/25 mcg
responder rate · % of participants
NCT03034915 · Phase 4 · registry result, not featured evidence
CAT -3.5 vs -3.4 UMEC score @ 24wk62.5/25 mcg
absolute change · score
NCT03034915 · Phase 4 · registry result, not featured evidence
Exercise Endurance Time Seconds -2.06 vs -5.37 placebo seconds @ 12wk62.5/25 mcg
absolute value · seconds
NCT02275052 · Phase 4 · registry result, not featured evidence
FRC Change -0.457 vs -0.111 placebo L @ 12wk62.5/25 mcg
absolute change · L
NCT02275052 · Phase 4 · registry result, not featured evidence

+ 6 further endpoints in the CSV export.

Asthma

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline

fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule combination
Reliable signal

NCT02924688 · Phase 3 · completed

This was a large (N=2,436) randomized, triple-blind, active-controlled Phase III trial comparing four fixed-dose combinations of fluticasone furoate/umeclidinium/vilanterol against two fluticasone furoate/vilanterol dual therapy controls in patients with inadequately controlled asthma. The primary endpoint, change from baseline in trough FEV1 at Week 24, was met for every pre-specified triple-therapy versus dual-therapy comparison, with all four least-squares mean differences favoring triple therapy and p<0.001. The combination of randomization, blinding, an active comparator, a large sample, a hard clinical endpoint, and a statistically significant primary result constitutes strong evidence.

Next expected readout: January 2027 · NCT05757102 (registry estimate)

Reported efficacy

Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 (Baseline (pre-dose at Day 1) and Week 24): Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001). (met)

Result source: NCT02924688

Umeclidinium · Incruse Ellipta

Marketed by GlaxoSmithKline

Phase 2 in Asthmasmall molecule
Partial signal

NCT01573624 · Phase 2 · completed

The study randomized 421 participants to three 14-day treatment periods and kept participants and investigators blinded, with active comparator arms. Its primary outcomes were lung-function measures rather than hard clinical outcomes, and the results were mixed: trough FEV1 was significantly higher with the 125- and 250-mcg UMEC doses but not with the lower doses.

Reported efficacy

Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period); Percentage of Chance That FF 100 mcg Alone Corrected Change From Baseline FEV1 Response Would Exceed a Target Response by Dose of UMEC Combined With FF 100 mcg (Baseline (Day 1) and Day 15 of each treatment period); Mean Change From Baseline in Trough FEV1 on Day 15 of Each of the 3 Treatment Periods (Baseline (Day 1) and Day 15 of each treatment period): Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period): FF 100 mcg + UMEC 15.6 mcg 0.026 Litres (L) (95% CI -0.0098 to 0.0611) | FF 100 mcg + UMEC 31.25 mcg 0.032 Litres (L) (95% CI -0.0036 to 0.0679) | FF 100 mcg + UMEC 62.5 mcg 0.0385 Litres (L) (95% CI -0.0011 to 0.0745) | FF 100 mcg + UMEC 125 mcg 0.0444 Litres (L) (95% CI 0.0067 to 0.0813) | FF 100 mcg + UMEC 250 mcg 0.051 Litres (L) (95% CI 0.0139 to 0.0873) (mixed)

Result source: NCT01573624

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfluticasone furoate/​umeclidinium/​vilanterolUmeclidinium
Severe exacerbations, annualised rate—Trial running · NCT04651777—Trial running · NCT04651777
Trough FEV1, change0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 FF 100 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 87 · Phase 3 · primary NCT04937387
  • 0.1 vs 0.1 FF 200 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 82 · Phase 3 · secondary NCT04937387
0.3 vs 0.1+0.2 vs placebo31.25 mcg QD · wk 24 · n 136NCT03012061
17 other results
  • 0.1 vs 0.0 31.25 µg QD · wk 2 · n 124 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 31.25 µg BID · wk 2 · n 118 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 250 µg QD · wk 2 · n 117 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 125 µg QD · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.3 vs 0.1 62.5 mcg QD · wk 24 · n 139 · Phase 2 · primary NCT03012061
  • 0.1 vs 0.0 62.5 µg QD · wk 2 · n 122 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg QD · wk 2 · n 120 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg BID · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.2 100 mcg + 15.6 mcg · wk 2 · n 154 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 31.25 mcg · wk 2 · n 146 · Phase 2 · primary NCT01573624
  • 0.1 vs 0.2 100 mcg + 62.5 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 125 mcg · wk 2 · n 155 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 250 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539
ACQ-5, change—Trial running · NCT04651777—Trial running · NCT04651777
OCS dose reduction—Trial running · NCT04651777—Trial running · NCT04651777

Severe exacerbations, annualised rate

fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777
Umeclidinium
—Trial running · NCT04651777

Trough FEV1, change

fluticasone furoate/​umeclidinium/​vilanterol
0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 FF 100 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 87 · Phase 3 · primary NCT04937387
  • 0.1 vs 0.1 FF 200 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 82 · Phase 3 · secondary NCT04937387
Umeclidinium
0.3 vs 0.1+0.2 vs placebo31.25 mcg QD · wk 24 · n 136NCT03012061
17 other results
  • 0.1 vs 0.0 31.25 µg QD · wk 2 · n 124 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 31.25 µg BID · wk 2 · n 118 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 250 µg QD · wk 2 · n 117 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 125 µg QD · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.3 vs 0.1 62.5 mcg QD · wk 24 · n 139 · Phase 2 · primary NCT03012061
  • 0.1 vs 0.0 62.5 µg QD · wk 2 · n 122 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg QD · wk 2 · n 120 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg BID · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.2 100 mcg + 15.6 mcg · wk 2 · n 154 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 31.25 mcg · wk 2 · n 146 · Phase 2 · primary NCT01573624
  • 0.1 vs 0.2 100 mcg + 62.5 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 125 mcg · wk 2 · n 155 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 250 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539

ACQ-5, change

fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777
Umeclidinium
—Trial running · NCT04651777

OCS dose reduction

fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777
Umeclidinium
—Trial running · NCT04651777
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. fluticasone furoate/umeclidinium/vilanterol: 5 of 5 rows · Umeclidinium: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfluticasone furoate/​umeclidinium/​vilanterolUmeclidinium
FEV1 Change 3 h
absolute change · L
0.22 vs 0.132 FF/VI L @ 24wk100/31.25/25 mcga,b,c,d
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 3 more doses
0.256 vs 0.132 FF/VI L @ 24wk200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.243 vs 0.132 FF/VI L @ 24wk100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.286 vs 0.132 FF/VI L @ 24wk200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.3663 vs 0.1768 placebo L @ 24wk31.25 mcg QDa,b,c,d
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
show 1 more dose
0.3744 vs 0.1768 placebo L @ 24wk62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
Dropout rate
7.7%100/31.25/25 mcge
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.9%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
3.4%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
0%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
11.1%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
7.3%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
—100 mcg + 125 mcgf
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 19 more results
—100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
5.9%31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
2%31.25 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
5.1%250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
9.3%125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
—31.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
6.5%31.25 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
5.8%62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
3.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
4.3%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
2.5%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
0.7%100/31.25/25 mcge
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
0.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.5%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.5%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
0%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
1.8%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
—100 mcg + 125 mcgf
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 19 more results
—100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%31.25 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
—31.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%31.25 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
0%62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
—100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
4.4%100/31.25/25 mcge
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.1%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
1.1%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
3.3%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
3.6%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
0%100 mcg + 125 mcgf
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 19 more results
0%100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.6%100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
—31.25 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.7%250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%31.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
2.9%31.25 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
2.2%62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
0.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
100/31.25/25 mcge
nasopharyngitis 13.8%
headache 7.7%
upper respiratory tract infection 5.9%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
200/31.25/25 mcg
nasopharyngitis 12.6%
headache 6.7%
bronchitis 4%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
100/62.5/25 mcg
nasopharyngitis 14.8%
headache 8.9%
bronchitis 3.7%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
200/62.5/25 mcg
nasopharyngitis 12.5%
bronchitis 5.4%
headache 4.7%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
FF 200 ug, UMEC 62.5 ug, VI 25 ug
covid-19 5.7%
nasopharyngitis 4.5%
upper respiratory tract infection 4.5%
NCT04937387 · Phase 3 · Asthma · phase 3
FF 100 ug, UMEC 62.5 ug, VI 25 ug
upper respiratory tract infection 7.8%
covid-19 3.3%
nasopharyngitis 3.3%
NCT04937387 · Phase 3 · Asthma · phase 3
100/62.5/25 mcg
nasopharyngitis 27.7%
pharyngitis 10.6%
bronchitis 8.5%
NCT03184987 · Phase 3 · combination
100/62.5/25 mcg to 200/62.5/25 mcg
bronchitis 22.2%
dysgeusia 22.2%
nasopharyngitis 22.2%
NCT03184987 · Phase 3 · combination
200/62.5/25 mcg
nasopharyngitis 32.7%
dysgeusia 10.9%
eczema 9.1%
NCT03184987 · Phase 3 · combination
100 mcg + 125 mcgf
headache 2.3%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 18 more results
100 mcg + 15.6 mcg
headache 2.2%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
100 mcg + 250 mcg
headache 3.8%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
100 mcg + 31.25 mcg
headache 1.1%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
100 mcg + 62.5 mcg
headache 2.8%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
31.25 µg BID
headache 4.5% (placebo 1.6%)
nasopharyngitis 1.5% (placebo 0.8%)
pharyngitis 0% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
250 µg QD
headache 4.4% (placebo 1.6%)
product taste abnormal 3.7% (placebo 0%)
nasopharyngitis 0.7% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
125 µg QD
headache 3.1% (placebo 1.6%)
product taste abnormal 3.1% (placebo 0%)
nasopharyngitis 2.3% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
62.5 µg QD
headache 3.8% (placebo 1.6%)
pharyngitis 3.8% (placebo 0.8%)
nasopharyngitis 0.8% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
31.5 µg QD
headache 2.9% (placebo 1.6%)
product taste abnormal 1.4% (placebo 0%)
pharyngitis 0.7% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
15.6 µg BID
nasopharyngitis 3.2% (placebo 0.8%)
headache 1.6% (placebo 1.6%)
pharyngitis 0.8% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
15.6 µg QD
headache 3.8% (placebo 1.6%)
nasopharyngitis 2.3% (placebo 0.8%)
pharyngitis 0% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
31.25 mcg QD
nasopharyngitis 10.1% (placebo 11.9%)
headache 6.5% (placebo 7.7%)
upper respiratory tract infection 5.8% (placebo 2.1%)
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
62.5 mcg QD
nasopharyngitis 9.4% (placebo 11.9%)
headache 8.6% (placebo 7.7%)
upper respiratory tract infection 4.3% (placebo 2.1%)
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
100/250 µg
nasopharyngitis 1.9%
toothache 0.5%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/125 µg
dysphonia 6.5%
nasopharyngitis 4.3%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/15.6 µg
nasopharyngitis 7.1%
toothache 7.1%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/62.5 µg
nasopharyngitis 5%
dysphonia 2.5%
toothache 2.5%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/250/25 µg
dysphonia 0%
nasopharyngitis 0%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 2.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context differs: combination versus background therapy.
  5. ePopulation comparability has not been reviewed for 3 of these studies.
  6. fPopulation comparability has not been reviewed for 7 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

fluticasone furoate/umeclidinium/vilanterol

ACQ-7 -0.814 vs -0.94 Fluticasone Furoate [FF] / Vilanterol [VI] score @ 12wkFF 200 ug, UMEC 62.5 ug, VI 25 ug
absolute change · score
NCT04937387 · Phase 3 · Asthma · phase 3
show 1 more result
-0.968 vs -0.94 Fluticasone Furoate [FF] / Vilanterol [VI] score @ 12wkFF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3

Umeclidinium

FEV1 Trough 0.026 L @ 2wk100 mcg + 15.6 mcg
absolute change · L
No placebo or comparator arm
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 4 more results
0.032 L @ 2wk100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.0385 L @ 2wk100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.0444 L @ 2wk100 mcg + 125 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.051 L @ 2wk100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
Morning PEF 13 vs -2.9 FF L100 mcg + 15.6 mcg
absolute change · L
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 4 more results
14.5 vs -2.9 FF L100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
15.7 vs -2.9 FF L100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
20 vs -2.9 FF L100 mcg + 125 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
19 vs -2.9 FF L100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
Evening PEF 11.1 vs -5.2 FF L/min100 mcg + 15.6 mcg
absolute change · L/min
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 4 more results
12.1 vs -5.2 FF L/min100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
16 vs -5.2 FF L/min100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
23.7 vs -5.2 FF L/min100 mcg + 125 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
17.7 vs -5.2 FF L/min100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
FEV1 Wm0 24 h 0.077 vs -0.025 placebo L @ 2wk31.25 µg QD
absolute change · L
NCT01641692 · Phase 2 · combination · Asthma · phase 2
show 6 more results
0.043 vs -0.025 placebo L @ 2wk31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.048 vs -0.025 placebo L @ 2wk250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.094 vs -0.025 placebo L @ 2wk125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.092 vs -0.025 placebo L @ 2wk62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.06 vs -0.025 placebo L @ 2wk15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.097 vs -0.025 placebo L @ 2wk15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
Evening PEF Change L/Min 1.5 vs -5.1 placebo L/min @ 2wk31.25 µg QD
absolute change · L/min
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
show 6 more results
8.7 vs -5.1 placebo L/min @ 2wk31.25 µg BID
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
9.3 vs -5.1 placebo L/min @ 2wk250 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
9.8 vs -5.1 placebo L/min @ 2wk125 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
-0.9 vs -5.1 placebo L/min @ 2wk62.5 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
10 vs -5.1 placebo L/min @ 2wk15.6 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
2.5 vs -5.1 placebo L/min @ 2wk15.6 µg BID
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
Rescue Puffs -0.2 vs 0.6 FF Puffs @ 4wk100/250 µg
absolute change · Puffs
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
0 vs 0.6 FF Puffs @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-0.4 vs 0.6 FF Puffs @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-0.5 vs 0.6 FF Puffs @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
E-RS Total -1.5 vs 0.5 FF score @ 4wk100/250 µg
absolute change · score
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
-1.5 vs 0.5 FF score @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-2.6 vs 0.5 FF score @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-2.5 vs 0.5 FF score @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Morning PEF 10.5 vs -14.2 FF L/min @ 4wk100/250 µg
absolute change · L/min
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
5.5 vs -14.2 FF L/min @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
3.9 vs -14.2 FF L/min @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
7.6 vs -14.2 FF L/min @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/umeclidinium/vilanterol's landscape · Umeclidinium's landscape